The Intercept | September 14, 2023
“The FDA does have a certain amount of post-market surveillance, but it’s not going to be really tracking these supplies that are not opioids or some other restricted product,” Lawrence Gostin, director of Georgetown University’s O’Neill Institute for National and Global Health Law, told The Intercept. “I think as a practical matter, it’ll be very, very difficult for the company to control who gets access to its products.”